Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742859 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
A Phase 2 study, sponsored by Portola Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 508
- Enrollment target
NCT00742859 is a Phase 2 study that has completed, run by Portola Pharmaceuticals. The registered enrollment target is 508 participants.
The verdict
NCT00742859, a Phase 2 study, has completed, sponsored by Portola Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 508 participants
- Enrollment target
Study Summary
Prevention of stroke in patients with atrial fibrillation (AF). Hypothesis: In patients with non-valvular AF, orally administered betrixaban will provide similar or better efficacy and safety than warfarin and it will offer the advantage of not requiring dose adjustments due to international normalized ratios (INRs) outside the target range of 2.0 to 3.0 and a more consistent level of anticoagulation over time.
Interventions
- DRUG Warfarin
- DRUG betrixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00742859
The ClinicalTrials.gov registry entry for NCT00742859 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Portola Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT00742859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00742859 about?
NCT00742859 is a clinical study titled "Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin". Prevention of stroke in patients with atrial fibrillation (AF). Hypothesis: In patients with non-valvular AF, orally administered betrixaban will provide similar or better efficacy and safety than warfarin and it will offer the advantage of not requiring dose adjustments due to international normali...
What is the current status of trial NCT00742859?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 508 participants. The study started on 2008-10. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00742859?
The interventions under investigation include: Warfarin (DRUG), betrixaban (DRUG).
Who is sponsoring clinical trial NCT00742859?
This trial is sponsored by Portola Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.